Innoviva, Inc. (INVA)
22.03
+0.06
(+0.27%)
USD |
NASDAQ |
Mar 13, 16:00
22.05
+0.02
(+0.09%)
After-Hours: 20:00
Innoviva EPS Diluted (Quarterly) : 1.944 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Merck & Co., Inc. | 1.191 |
| Nektar Therapeutics | -1.778 |
| Regeneron Pharmaceuticals, Inc. | 7.857 |
| Oramed Pharmaceuticals, Inc. | 1.131 |
| Theravance Biopharma, Inc. | 0.0696 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 164.15M |
| Revenue (Quarterly) | 118.04M |
| Total Expenses (Quarterly) | -46.11M |
| Enterprise Value | 1.334B |
| Gross Profit Margin (Quarterly) | 64.05% |
| Earnings Yield | 13.87% |
| Operating Earnings Yield | 9.37% |
| Normalized Earnings Yield | 8.887 |